Showing results (151-160 of 160) with videos related to
Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
The Lancet. Gastroenterology & Hepatology|February 24, 2020
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority studyPietro Lampertico, Maria Buti, Scott Fung, et al.Journal of Hepatology|May 11, 2024
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trialHeiner Wedemeyer, Soo Aleman, Maurizia Brunetto, et al.JHEP Reports : Innovation in Hepatology|September 29, 2023
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis BYoung-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, et al.The Lancet. Gastroenterology & Hepatology|April 14, 2017
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trialHenry L Y Chan, Scott Fung, Wai Kay Seto, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 23, 2018
Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV InfectionWai-Kay Seto, Yasuhiro Asahina, Todd T Brown, et al.Alimentary Pharmacology & Therapeutics|September 27, 2024
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trialsMaria Buti, Young-Suk Lim, Henry Lik Yuen Chan, et al.Journal of Hepatology|May 15, 2018
96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infectionKosh Agarwal, Maurizia Brunetto, Wai Kay Seto, et al.Journal of Hepatology|July 25, 2020
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitisRong Fan, George Papatheodoridis, Jian Sun, et al.JAMA Pediatrics|May 2, 2022
Association of Diagnostic Stewardship for Blood Cultures in Critically Ill Children With Culture Rates, Antibiotic Use, and Patient Outcomes: Results of the Bright STAR CollaborativeCharlotte Z Woods-Hill, Elizabeth A Colantuoni, Danielle W Koontz, et al.JAMA Network Open|July 31, 2026
Diagnostic Stewardship of Respiratory Cultures Using Clinical Decision Support in the PICUAnna C Sick-Samuels, Charlotte Z Woods-Hill, Daniel P Kelly, et al.Pageof 16